JPWO2023095802A5 - - Google Patents

Info

Publication number
JPWO2023095802A5
JPWO2023095802A5 JP2023563705A JP2023563705A JPWO2023095802A5 JP WO2023095802 A5 JPWO2023095802 A5 JP WO2023095802A5 JP 2023563705 A JP2023563705 A JP 2023563705A JP 2023563705 A JP2023563705 A JP 2023563705A JP WO2023095802 A5 JPWO2023095802 A5 JP WO2023095802A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cells
disease
composition according
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563705A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023095802A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/043221 external-priority patent/WO2023095802A1/ja
Publication of JPWO2023095802A1 publication Critical patent/JPWO2023095802A1/ja
Publication of JPWO2023095802A5 publication Critical patent/JPWO2023095802A5/ja
Pending legal-status Critical Current

Links

JP2023563705A 2021-11-24 2022-11-22 Pending JPWO2023095802A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021190125 2021-11-24
PCT/JP2022/043221 WO2023095802A1 (ja) 2021-11-24 2022-11-22 T細胞関連疾患を治療または予防するための医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2023095802A1 JPWO2023095802A1 (https=) 2023-06-01
JPWO2023095802A5 true JPWO2023095802A5 (https=) 2025-10-29

Family

ID=86539431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563705A Pending JPWO2023095802A1 (https=) 2021-11-24 2022-11-22

Country Status (9)

Country Link
US (1) US20250352578A1 (https=)
EP (1) EP4438048A4 (https=)
JP (1) JPWO2023095802A1 (https=)
KR (1) KR20240130083A (https=)
CN (1) CN118591379A (https=)
CA (1) CA3238860A1 (https=)
MX (1) MX2024006370A (https=)
TW (1) TW202334397A (https=)
WO (1) WO2023095802A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
WO2024204553A1 (ja) * 2023-03-29 2024-10-03 レグセル株式会社 ヒト誘導性制御性t細胞およびその作製方法、およびt細胞関連疾患を治療または予防するための医薬組成物
JP2025064863A (ja) * 2023-10-06 2025-04-17 株式会社マイオリッジ T細胞の培養方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101883844A (zh) * 2007-10-12 2010-11-10 分子医学马克斯德尔布吕克中心 快速分离人Foxp3+Treg细胞的方法和试剂盒
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
US20140309224A1 (en) 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
UA117342C2 (uk) 2012-02-02 2018-07-25 Сенекс Біотекнолоджи Інк. Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку
EP2888232A1 (en) 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
ES2698960T3 (es) 2012-10-08 2019-02-06 Merck Patent Gmbh Compuestos de 2-aminopiridina
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
JP2016501251A (ja) 2012-12-10 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための新規二環フェニル−ピリジン/ピラジン
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Cdk8之醫療性抑制劑及其用途
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
JP6434989B2 (ja) 2014-03-27 2018-12-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピリジルピペリジン
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6521387B2 (ja) 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CA3051469A1 (en) * 2017-01-27 2018-08-02 Abraham J And Phyllis Katz Cord Blood Foundation T cells derived from umbilical cord blood
US11578067B2 (en) 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
US20210238551A1 (en) * 2018-08-22 2021-08-05 Osaka University Method for Generating Regulatory T Cells
EP3880213A4 (en) * 2018-11-13 2022-11-23 Abraham J and Phyllis Katz Cord Blood Foundation T CELLS WITH IMPROVED MITOCHONDRIAL FUNCTION
US20220018835A1 (en) * 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
KR20210149201A (ko) * 2019-04-30 2021-12-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 인간 조절 t 세포의 비드-무함유 생체외 확장
US20210373951A1 (en) 2020-05-28 2021-12-02 Samsung Electronics Co., Ltd. Systems and methods for composable coherent devices
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4532697A2 (en) * 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
EP4596684A1 (en) * 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)

Similar Documents

Publication Publication Date Title
JPWO2023095802A5 (https=)
Martinez et al. Can we cure hepatitis B virus with novel direct‐acting antivirals?
Ramírez-Valle et al. Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17–driven responses
Rivera et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer
JP2016204396A5 (https=)
Scherl et al. Review of the safety and efficacy of ustekinumab
Bucala Neuroimmunomodulation by macrophage migration inhibitory factor (MIF)
JP2024075624A5 (https=)
Post et al. Some effects of tritiated thymidine as a deoxyribonucleic acid label in the rat liver
KR20240063969A (ko) 클리스트리디움 곤디 포자와 펨브롤리주맙의 연합의 응용
Lu et al. Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model
Pal et al. Trained Innate Immunity
Evensen Kinetics of epidermal cell proliferation in experimental skin carcinogenesis
CN111154712A (zh) 一种Spexin促进胰岛素的分泌和胰岛细胞增殖的方法
Karlson The combined use of Ethambutol (Dextro-2, 2′-[Ethylenediimino]-Di-l-Butanol) and Isoniazid in experimental tuberculosis of Guinea pigs
Bauer et al. Stem cell transplantation in the context of HIV–how can we cure HIV infection?
Luo et al. An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
Montgomery et al. Next generation miR-29 mimics as a therapy for pulmonary fibrosis
WO2026037423A1 (zh) IFN-γmRNA的反义寡核苷酸及其应用和药用组合物
Fernández-Ruiz Deleterious role of IDO1 in cardiac repair
Liu et al. Alterations in Cerebellar Expressions of JAK2 Signaling-Related Genes in SCA3 Mice After Growth Hormone Therapy
Fernández-Ruiz Lipid metabolism in peripartum cardiomyopathy
Figueiredo et al. NK1. 1 cells downregulate murine endotoxin‐induced uveitis following intraocular administration of interleukin‐12
Minvielle U et al. The use of intralesional triamcinolone hexacetonide in treatment of idiopathic pruritus ani
Truong et al. PREVENTION OF DNA REREPLICATION